The INTERCEPT study is being funded to the tune of €38 million (nearly $40 million) over the next five years and is described ...
Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral ...
StudyFinds on MSN2d
Your smartwatch could predict IBD flares weeks before they happenDiscover how wearable devices like Apple Watches and Fitbits can detect signs of IBD flares weeks before symptoms appear, ...
Many with Crohn’s disease or ulcerative colitis sacrifice essential purchases like food and clothing for healthcare, survey ...
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.
Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...
Health on MSN3d
10 Conditions Turmeric Can Help WithTurmeric's active compound, curcumin, is a potent anti-inflammatory and antioxidant that can help with conditions like ...
Researchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...
The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...
Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...
Hosted on MSN5d
Scientists Make Groundbreaking Discovery in the Search for the Cause of Inflammatory Bowel DiseaseIn a major breakthrough, researchers in the UK have discovered a potential root cause of inflammatory bowel disease (IBD), a ...
Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback